Welcome to the Molecular Glue Drug Development Summit!
The Molecular Glue Drug Development Summit is back in January, 2025!
Newsletters and Deep Dive digital magazine
The Molecular Glue Drug Development Summit is back in January, 2025!
Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.
RNAi-Based Therapeutics Returns!
Anglo-US contract development and manufacturing organisation (CDMO) Avid Bioservices has agreed a deal to be acquired by private equity firms GHO Capital Partners and Ampersand Capital Part
As the pharmaceutical industry continues its shift towards more patient-centric models, the incorporation of social determinants of health (SDOH) data has become increasingly valuable.
Editor's Picks
Newsletters and Deep Dive
digital magazine